Synonyms: BMS-790052 | BMS790052 | Daklinza®
daclatasvir is an approved drug (EMA (2014), FDA (2015))
Compound class:
Synthetic organic
Comment: Daclatasvir is an orally available anti-hepatitis C virus (HCV) drug, It is a direct-acting inhibitor of the non-structural protein 5A (NS5A) replication complex of HCV [1]. Blocking NS5A function inhibits viral RNA replication and virion assembly.
|
|
Bioactivity Comments |
Daclatasvir exhibits picomolar EC50s towards replicons expressing a broad range of HCV genotypes [1]. |